Stoke Therapeutics Receives Overweight Rating with $40 Price Target

Stoke Therapeutics (STOK) received an 'overweight' rating from analysts at JPMorgan Chase & Co., who set a price target of $40.00 on the stock.

This suggests a potential upside of 25.23% from the company's previous close of $31.94.

The firm's coverage comes after several other analysts have commented on STOK, including Chardan Capital and The Goldman Sachs Group, which both reiterate 'buy' ratings with price targets of $35.00 and $44.00 respectively.